Shares in Sarepta Therapeutics, Inc. have slid after a keenly anticipated study showed that SRP-9001, its investigational gene therapy for Duchenne muscular dystrophy (DMD), failed to significantly improve muscle function, dealing a blow to hopes that the one-time treatment would get approval for the devastating childhood disease any time soon.
Sarepta Sinks On Mixed DMD Gene Therapy Study
Blames 'Bad Luck In Randomization Process'
Any time advantage Sarepta's Duchenne muscular dystrophy gene therapy may have had over rivals, notably Pfizer, has disappeared after SRP-9001 failed to significantly improve muscle function in a closely watched trial.
More from Gene Therapies
• By
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
• By
The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.
• By
Adstiladrin sales hit €70m in first full year on the market
• By
Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?
More from Advanced Therapies
• By
The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.
• By
Adstiladrin sales hit €70m in first full year on the market
• By
The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.